

STEFAN J. KLAUBER
DAVID A. JACKSON
STEVE S. CHA
VALETA A. GREGG, PH.D.^{*}
STEPHEN GIGANTE
LAWRENCE D. MANDEL⁺
CATHERINE ROSEMAN SMITH*

*BAR OTHER THAN N.J.
+ COUNSEL

PATENT AGENTS

CHRISTINE E. DIETZEL, PH.D.
MICHAEL A. YAMIN, PH.D.

SCIENTIFIC ADVISOR

VERONICA M. MALLON, PH.D.

KLAUBER & JACKSON
ATTORNEYS AT LAW
CONTINENTAL PLAZA
411 HACKENSACK AVENUE
HACKENSACK, NEW JERSEY 07601

03 CO
#8
PATENT, TRADEMARK AND
COPYRIGHT CAUSES
(201) 487-5800
FACSIMILE: (201) 343-1684
WWW.KJIPOLAW.COM
email: info@kjiplaw.com

May 22, 2002

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Re: U.S. Patent Application
Inventors: Mary Jeanne Kreek and Karl Steven La Forge
Title: ALLELES OF THE HUMAN ORPHANIN FQ/NOCICEPTIN
RECEPTOR GENE, DIAGNOSTIC METHODS USING SAID
ALLELES, AND METHODS OF TREATMENT BASED
THEREON
Serial No.: 09/905,186
Filed: July 13, 2001
Our Ref.: 600-1-284 N

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box Sequence, PO Box 2327, Arlington, VA 22202 on May 22, 2002.

David A. Jackson, Reg. No. 26,742
(Name of Registered Representative)

(Signature and Date)

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES

Sir:

Responsive to the Notice dated April 15, 2002, with a due date of June 15, 2002, indicating that the previously forwarded Sequence Listing Disk was damaged, and in accordance with 37 CFR 1.821 - 1.825, Applicants submit herewith the following:

Assistant Commissioner for Patents
May 22, 2002
Page 2


Attorney Docket No.: 600-1-284 N

1. A paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims.
2. A copy of the Sequence Listing in computer readable form.
3. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 - 1.825.

Applicants request favorable consideration and entry of the Sequence Listing submitted herewith and further and favorable processing of the present Application.

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

DAJ:aj
Enclosures

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/905,186

Filing Date: 7/13/2001

Date Processed by STIC: 2/7/2002

STIC Contact: Mark Spencer, 703-308-4212

Nature of Problem:

The CRF (was):

- (circle one) Damaged or Unreadable (for Unreadable, see attached)
 Blank (no files on CRF) (see attached)
 Empty file (filename present, but no bytes in file) (see attached)
 Virus-infected. Virus name: _____ The STIC will not process the CRF.
 Not saved in ASCII text
 Sequence Listing was embedded in the file. According to Sequence Rules,
 submitted file should **only** be the Sequence Listing.
 Did not contain a Sequence Listing. (see attached sample)
 Other: _____

PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.

SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service , or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/905,186	10/09/2001	Mary Jeanne Kreek	600-1-284N

23565
KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NJ 07601

CONFIRMATION NO. 3062
FORMALITIES LETTER



OC00000007863653

Date Mailed: 04/15/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE